PMID- 37272996
OWN - NLM
STAT- MEDLINE
DCOM- 20240124
LR  - 20240201
IS  - 1439-099X (Electronic)
IS  - 0179-7158 (Print)
IS  - 0179-7158 (Linking)
VI  - 200
IP  - 2
DP  - 2024 Feb
TI  - Radiotherapy concepts for spinal metastases-results from an online survey among 
      radiation oncologists of the German Society for Radiation Oncology.
PG  - 159-174
LID - 10.1007/s00066-023-02082-w [doi]
AB  - PURPOSE: Spinal metastases (SM) are a common radiotherapy (RT) indication. There 
      is limited level I data to drive decision making regarding dose regimen (DR) and 
      target volume definition (TVD). We aim to depict the patterns of care for RT of 
      SM among German Society for Radiation Oncology (DEGRO) members. METHODS: An 
      online survey on conventional RT and Stereotactic Body Radiation Therapy (SBRT) 
      for SM, distributed via e‑mail to all DEGRO members, was completed by 
      80 radiation oncologists between February 24 and April 29, 2022. Participation 
      was voluntary and anonymous. RESULTS: A variety of DR was frequently used for 
      conventional RT (primary: n = 15, adjuvant: n = 14). 30 Gy/10 fractions was 
      reported most frequently. TVD in adjuvant RT was heterogenous, with a trend 
      towards larger volumes. SBRT was offered in 65% (primary) and 21% (adjuvant) of 
      participants' institutions. A variety of DR was reported (primary: n = 40, 
      adjuvant: n = 27), most commonly 27 Gy/3 fractions and 30 Gy/5 fractions. 59% 
      followed International Consensus Guidelines (ICG) for TVD. CONCLUSION: We provide 
      a representative depiction of RT practice for SM among DEGRO members. DR and TVD 
      are heterogeneous. SBRT is not comprehensively practiced, especially in the 
      adjuvant setting. Further research is needed to provide a solid data basis for 
      detailed recommendations.
CI  - (c) 2023. The Author(s).
FAU - Waltenberger, Maria
AU  - Waltenberger M
AUID- ORCID: 0000-0002-8064-0010
AD  - Department of Radiation Oncology, Klinikum rechts der Isar, Technical University 
      of Munich (TUM), Munich, Germany. maria.waltenberger@mri.tum.de.
AD  - German Cancer Consortium (DKTK), partner site Munich, Munich, Germany. 
      maria.waltenberger@mri.tum.de.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany. 
      maria.waltenberger@mri.tum.de.
FAU - Vogel, Marco M E
AU  - Vogel MME
AD  - Department of Radiation Oncology, Klinikum rechts der Isar, Technical University 
      of Munich (TUM), Munich, Germany.
FAU - Bernhardt, Denise
AU  - Bernhardt D
AD  - Department of Radiation Oncology, Klinikum rechts der Isar, Technical University 
      of Munich (TUM), Munich, Germany.
FAU - Munch, Stefan
AU  - Munch S
AD  - Department of Radiation Oncology, Klinikum rechts der Isar, Technical University 
      of Munich (TUM), Munich, Germany.
FAU - Dobiasch, Sophie
AU  - Dobiasch S
AD  - Department of Radiation Oncology, Klinikum rechts der Isar, Technical University 
      of Munich (TUM), Munich, Germany.
AD  - German Cancer Consortium (DKTK), partner site Munich, Munich, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
AD  - Institute of Radiation Medicine (IRM), Helmholtz Zentrum, Munich, Germany.
FAU - Redmond, Kristin J
AU  - Redmond KJ
AD  - Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins 
      University School of Medicine, Baltimore, USA.
FAU - Lo, Simon S
AU  - Lo SS
AD  - Department of Radiation Oncology, University of Washington School of Medicine, 
      Seattle, USA.
FAU - Acker, Guliz
AU  - Acker G
AD  - Department of Neurosurgery, Charite Universitatsmedizin Berlin (Corporate Member 
      of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute 
      of Health), Berlin, Germany.
AD  - Department of Radiation Oncology, Charite Universitatsmedizin Berlin (Corporate 
      Member of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin 
      Institute of Health), Berlin, Germany.
AD  - Berlin Institute of Health, Berlin, Germany.
FAU - Fehlings, Michael G
AU  - Fehlings MG
AD  - Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, 
      Canada.
FAU - Ringel, Florian
AU  - Ringel F
AD  - Department of Neurosurgery, University Hospital Mainz, Mainz, Germany.
FAU - Vajkoczy, Peter
AU  - Vajkoczy P
AD  - Department of Neurosurgery, Charite Universitatsmedizin Berlin (Corporate Member 
      of Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute 
      of Health), Berlin, Germany.
FAU - Meyer, Bernhard
AU  - Meyer B
AD  - Department of Neurosurgery, Klinikum rechts der Isar, Technical University of 
      Munich (TUM), Munich, Germany.
FAU - Combs, Stephanie E
AU  - Combs SE
AD  - Department of Radiation Oncology, Klinikum rechts der Isar, Technical University 
      of Munich (TUM), Munich, Germany.
AD  - German Cancer Consortium (DKTK), partner site Munich, Munich, Germany.
AD  - German Cancer Research Center (DKFZ), Heidelberg, Germany.
AD  - Institute of Radiation Medicine (IRM), Helmholtz Zentrum, Munich, Germany.
LA  - eng
PT  - Journal Article
DEP - 20230605
PL  - Germany
TA  - Strahlenther Onkol
JT  - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et 
      al]
JID - 8603469
SB  - IM
MH  - Humans
MH  - *Radiation Oncology
MH  - *Spinal Neoplasms/radiotherapy/secondary
MH  - Radiation Oncologists
MH  - Surveys and Questionnaires
MH  - *Radiosurgery/methods
PMC - PMC10805849
OTO - NOTNLM
OT  - Online survey
OT  - Palliation
OT  - Patterns of care
OT  - Radiotherapy
OT  - SBRT
OT  - Spinal metastases
COIS- K.J. Redmond has received research support, travel expenses, and honorarium for 
      educational seminars from Accuray; research support from Canon and Elekta; 
      participates in a data safety monitoring committee for BioMimetix; and received 
      travel expenses from Brainlab, Elekta, and Icotec. S.S. Lo is a member of the 
      Elekta Gamma Knife ICON Expert Group. F.R. is a consultant for Stryker, Brainlab 
      and Spineart and receives royalties from Spineart. B.M. discloses 
      honoraria/expenses, consulting/advisory board, and funded research from and for 
      Zeiss, Brainlab and Icotec. S.E. Combs reports grants from Deutsche 
      Forschungsgemeinschaft; non-financial support from Deutsches Konsortium fur 
      Translationale Krebsforschung; consulting fees, speaker agreements, travel 
      expenses, honoraria and non-financial support from Roche, AstraZeneca, Medac, Dr. 
      Sennewald Medizintechnik, Elekta, Accuray, BMS, Brainlab, Daiichi Sankyo, Icotec 
      AG, HMG Systems Engineering and Carl Zeiss Meditec AG. M. Waltenberger, 
      M.M.E. Vogel, D. Bernhardt, S. Munch, S. Dobiasch, G. Acker, M.G. Fehlings, 
      F. Ringel, P. Vajkoczy and B. Meyer declare that they have no competing 
      interests.
EDAT- 2023/06/05 13:04
MHDA- 2024/01/24 06:44
PMCR- 2023/06/05
CRDT- 2023/06/05 11:06
PHST- 2023/02/08 00:00 [received]
PHST- 2023/03/31 00:00 [accepted]
PHST- 2024/01/24 06:44 [medline]
PHST- 2023/06/05 13:04 [pubmed]
PHST- 2023/06/05 11:06 [entrez]
PHST- 2023/06/05 00:00 [pmc-release]
AID - 10.1007/s00066-023-02082-w [pii]
AID - 2082 [pii]
AID - 10.1007/s00066-023-02082-w [doi]
PST - ppublish
SO  - Strahlenther Onkol. 2024 Feb;200(2):159-174. doi: 10.1007/s00066-023-02082-w. 
      Epub 2023 Jun 5.